GlassScriptPhysician profile
William P Bowman
NPI 1578549226
$2,988.82
in general payments reported to CMS, 2019-2025
31 companies · $481 in 2025
The $481 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $506 · 2020: $265 · 2021: $239 · 2022: $572 · 2023: $485 · 2024: $441 · 2025: $481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,406.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $393.89 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $311.17 | 2019-2024 | Prolia, Evenity, Krystexxa |
| Pfizer INC. | $291.67 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $287.75 | 2020-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Novo Nordisk INC | $230.63 | 2019-2025 | Rybelsus, Ozempic |
| Abbvie INC. | $175.40 | 2021-2025 | Ubrelvy |
| Novartis Pharmaceuticals Corporation | $168.62 | 2021-2023 | |
| Terumo Medical Corporation | $143.30 | 2025 | Navicross, Glidewire |
| Medtronic Vascular, INC. | $125.67 | 2019 | |
| Amarin Pharma, INC. | $88.00 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $81.71 | 2019-2023 | Xarelto |
| Lilly USA, LLC | $75.98 | 2022-2024 | Jardiance, Trulicity, Mounjaro |
| Sanofi Pasteur INC. | $65.06 | 2020-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.04 | 2019-2024 | Jardiance, Ofev |
| Avanir Pharmaceuticals, INC. | $60.80 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $51.06 | 2022-2024 | Breztri |
| Dexcom, INC. | $44.83 | 2023-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.40 | 2025 | Xifaxan |
| Abbott Laboratories | $34.31 | 2022 | |
| Idorsia Pharmaceuticals US INC | $32.05 | 2023 | Quviviq |
| Philips North America LLC | $31.82 | 2022 | |
| Esperion Therapeutics, INC. | $31.80 | 2025 | Nexletol |
| Mayne Pharma Commercial LLC | $26.65 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $25.13 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $19.28 | 2021 | |
| Daiichi Sankyo INC. | $17.47 | 2022 | |
| Abiomed | $16.83 | 2024 | Impella |
| Almatica Pharma LLC | $15.75 | 2022 | |
| Sumitomo Pharma America, INC. | $15.11 | 2025 | Gemtesa |
| Dermira, INC. | $14.87 | 2020 | |
| Allergan, INC. | $11.77 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Bowman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.